Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

If you are considering both Ozempic and Zepbound for weight loss, it can be helpful to compare the two side by side before ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with ​its psoriatic ...

Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their ...

Friendly” labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased ...